Cargando…

A retinoic acid receptor β2 agonist attenuates transcriptome and metabolome changes underlying nonalcohol-associated fatty liver disease

Nonalcohol-associated fatty liver disease (NAFLD) is characterized by excessive hepatic accumulation of fat that can progress to steatohepatitis, and currently, therapeutic options are limited. Using a high-fat diet (HFD) mouse model of NAFLD, we determined the effects of the synthetic retinoid, AC2...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tang, Xiao-Han, Melis, Marta, Lu, Changyuan, Rappa, Andrew, Zhang, Tuo, Jessurun, Jose, Gross, Steven S., Gudas, Lorraine J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Biochemistry and Molecular Biology 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8626588/ https://www.ncbi.nlm.nih.gov/pubmed/34688661 http://dx.doi.org/10.1016/j.jbc.2021.101331

Ejemplares similares

Retinoic Acid Receptor β Loss in Hepatocytes Increases Steatosis and Elevates the Integrated Stress Response in Alcohol-Associated Liver Disease
por: Melis, Marta, et al.
Publicado: (2023)

Polycomb recruitment attenuates retinoic acid–induced transcription of the bivalent NR2F1 gene
por: Laursen, Kristian B., et al.
Publicado: (2013)

Effects of AM80 compared to AC261066 in a high fat diet mouse model of liver disease
por: Melis, Marta, et al.
Publicado: (2019)

Amyloid β inhibits retinoic acid synthesis exacerbating Alzheimer disease pathology which can be attenuated by an retinoic acid receptor α agonist
por: Goncalves, Maria B, et al.
Publicado: (2013)

Analyses of the Transcriptome and Metabolome Demonstrate That HIF1α Mediates Altered Tumor Metabolism in Clear Cell Renal Cell Carcinoma
por: Minton, Denise R., et al.
Publicado: (2015)

Obesity Leads to Tissue, but not Serum Vitamin A Deficiency
por: Trasino, Steven E., et al.
Publicado: (2015)

Transcriptomic analysis predicts the risk of progression of premalignant lesions in human tongue
por: Zhang, Tuo, et al.
Publicado: (2023)

Recent advances in nonalcoholic fatty liver disease metabolomics
por: Kim, Hwi Young
Publicado: (2021)

Combined Metabolomics and Genome-Wide Transcriptomics Analyses Show Multiple HIF1α-Induced Changes in Lipid Metabolism in Early Stage Clear Cell Renal Cell Carcinoma
por: van der Mijn, Johannes C., et al.
Publicado: (2019)

Retinoids in the Pathogenesis and Treatment of Liver Diseases
por: Melis, Marta, et al.
Publicado: (2022)

Attenuation of Hypertrophy in Human MSCs via Treatment with a Retinoic Acid Receptor Inverse Agonist
por: Riedl, Moritz, et al.
Publicado: (2020)

Utility of Metabolomic Biomarkers to Identify Nonalcoholic Fatty Liver Disease in Liver Transplant Recipients
por: Mowry, Christopher J., et al.
Publicado: (2021)

Serum metabolomic analysis of the effect of exercise on nonalcoholic fatty liver disease
por: Li, Jia, et al.
Publicado: (2019)

Serum metabolome alterations in patients with early nonalcoholic fatty liver disease
por: Wang, Xuemei, et al.
Publicado: (2022)

A Metabolomic Analysis of Omega-3 Fatty Acid-Mediated Attenuation of Western Diet-Induced Nonalcoholic Steatohepatitis in LDLR (-/-) Mice
por: Depner, Christopher M., et al.
Publicado: (2013)

Fenretinide Improves Intestinal Barrier Function and Mitigates Alcohol Liver Disease
por: Tang, Xiao-Han, et al.
Publicado: (2021)

Gut Microbiota and Nonalcoholic Fatty Liver Disease: Insights on Mechanism and Application of Metabolomics
por: He, Xuyun, et al.
Publicado: (2016)

Metabolomics Characterizes the Effects and Mechanisms of Quercetin in Nonalcoholic Fatty Liver Disease Development
por: Xu, Yan, et al.
Publicado: (2019)

Phosphorylation of 17β-hydroxysteroid dehydrogenase 13 at serine 33 attenuates nonalcoholic fatty liver disease in mice
por: Su, Wen, et al.
Publicado: (2022)

The Effects of PPAR Agonists on Atherosclerosis and Nonalcoholic Fatty Liver Disease in ApoE(−/−)FXR(−/−) Mice
por: Lee, Yenna, et al.
Publicado: (2021)

Serum metabolomic profile and potential biomarkers for severity of fibrosis in nonalcoholic fatty liver disease
por: Tokushige, Katsutoshi, et al.
Publicado: (2013)

Study of the Serum Metabolomic Profile in Nonalcoholic Fatty Liver Disease: Research and Clinical Perspectives
por: Gitto, Stefano, et al.
Publicado: (2018)

Metabolomic characteristics of cholesterol-induced non-obese nonalcoholic fatty liver disease in mice
por: Tu, Lan N., et al.
Publicado: (2017)

The Transcriptomic Signature Of Disease Development And Progression Of Nonalcoholic Fatty Liver Disease
por: Cazanave, Sophie, et al.
Publicado: (2017)

Hepatic transcriptome signatures in mice and humans with nonalcoholic fatty liver disease
por: Ding, Yiming, et al.
Publicado: (2023)

Lactobacillus attenuates progression of nonalcoholic fatty liver disease by lowering cholesterol and steatosis
por: Lee, Na Young, et al.
Publicado: (2021)

Sulforaphane Attenuates Nonalcoholic Fatty Liver Disease by Inhibiting Hepatic Steatosis and Apoptosis
por: Li, Jinwang, et al.
Publicado: (2021)

In silico discovery of novel Retinoic Acid Receptor agonist structures
por: Schapira, Matthieu, et al.
Publicado: (2001)

Heat stress and β-adrenergic agonists alter the adipose transcriptome and fatty acid mobilization in ruminant livestock()
por: Reith, Rachel R, et al.
Publicado: (2020)

PET/SPECT Molecular Probes for the Diagnosis and Staging of Nonalcoholic Fatty Liver Disease
por: Shao, Tuo, et al.
Publicado: (2019)

Glucagon-Like Peptide-1 Receptor Agonists for Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: An Updated Meta-Analysis of Randomized Controlled Trials
por: Mantovani, Alessandro, et al.
Publicado: (2021)

Urinary metabolomics analysis identifies key biomarkers of different stages of nonalcoholic fatty liver disease
por: Dong, Shu, et al.
Publicado: (2017)

Untargeted Metabolomic Analysis of the Effects and Mechanism of Nuciferine Treatment on Rats With Nonalcoholic Fatty Liver Disease
por: Cui, Huantian, et al.
Publicado: (2020)

Development of a Plasma Screening Panel for Pediatric Nonalcoholic Fatty Liver Disease Using Metabolomics
por: Khusial, Richard D., et al.
Publicado: (2019)

Adiposity, metabolomic biomarkers, and risk of nonalcoholic fatty liver disease: a case-cohort study
por: Pang, Yuanjie, et al.
Publicado: (2021)

Can metabolomic signature foster precision medicine approaches in nonalcoholic fatty liver disease arena?
por: Lonardo, Amedeo
Publicado: (2022)

All-Trans-Retinoic Acid Combined With Valproic Acid Can Promote Differentiation in Myeloid Leukemia Cells by an Autophagy Dependent Mechanism
por: Benjamin, Dalyia N., et al.
Publicado: (2022)

Pancreatic β-Cell Dysfunction Is Associated with Nonalcoholic Fatty Liver Disease
por: Chen, Xu, et al.
Publicado: (2021)

Assessment of the inter-platform reproducibility of ultrasound attenuation examination in nonalcoholic fatty liver disease
por: Jeon, Sun Kyung, et al.
Publicado: (2022)

Novel Retinoic Acid Receptor Alpha Agonists for Treatment of Kidney Disease
por: Zhong, Yifei, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_tu3rkg0hns6qtike9dajk8m7mu